|
| aminoglycoside therapy (N = 319) | no aminoglycoside therapy (N = 96) | p value |
| Gender |
|
| 0.130 |
| female | 148 (46.4%) | 53 (55.2%) |
|
| male | 171 (53.6%) | 43 (44.8%) |
|
| Age group |
|
| 0.108 |
| 15 - 25 | 77 (24.1%) | 33 (34.4%) |
|
| 26 - 35 | 76 (23.8%) | 26 (27.1%) |
|
| 36 - 45 | 65 (20.4%) | 17 (17.7%) |
|
| 46 - 55 | 27 (8.5%) | 8 (8.3%) |
|
| 55+ | 74 (23.2%) | 12 (12.5%) |
|
| BMI |
|
| 0.453 |
| Mean (SD) | 26.04 (4.63) | 24.98 (4.10) |
|
| Median (Q1, Q3) | 25.30 (22.95, 29.45) | 24.55 (22.52, 27.70) |
|
| Min - Max | 17.60 - 37.20 | 18.20 - 32.80 |
|
| Cardiovascular disease |
|
| 0.079 |
| no | 270 (84.6%) | 88 (91.7%) |
|
| yes | 49 (15.4%) | 8 (8.3%) |
|
| Lung disease |
|
| 0.968 |
| no | 306 (95.9%) | 92 (95.8%) |
|
| yes | 13 (4.1%) | 4 (4.2%) |
|